Literature DB >> 24074897

Pathological niche environment transforms dermal stem cells to keloid stem cells: a hypothesis of keloid formation and development.

Miao Qu1, Nang Song, Gang Chai, Xiaoli Wu, Wei Liu.   

Abstract

Keloid is a disease that is difficult to cure because of its high recurrence rate after chemotherapy or radiotherapy, therefore it is considered as a benign skin tumor. Tumor stem cells are proposed as the source for tumor development and post-therapy recurrence. Interestingly, keloid stem cells have also been discovered, which share some characters with those of skin progenitor cells. Keloid patients possess specific diathesis including genetic predisposition and gene mutation, abnormal levels of hormones, growth factors and cytokines, and strong inflammatory response. This article reviews related literatures and hypothesizes that keloid stem cells might be transformed from normal dermal progenitor cells in the pathological niche of keloid tissues. These keloid stem cells are highly self-renewal and drug resistant, and can sustain themselves by asymmetric division, and continually generate new keloid cells to replenish the cells killed by drugs or radiation, thus leading to over growth of keloid and high post-therapy recurrence rate.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24074897     DOI: 10.1016/j.mehy.2013.08.033

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  13 in total

Review 1.  Advances in the pathogenesis and clinical application prospects of tumor biomolecules in keloid.

Authors:  Yijun Xia; Youbin Wang; Mengjie Shan; Yan Hao; Hao Liu; Qiao Chen; Zhengyun Liang
Journal:  Burns Trauma       Date:  2022-06-25

Review 2.  The role of stem cells in benign tumors.

Authors:  Haiyan Qin; Dongyu Bao; Xin Tong; Qingang Hu; Guowen Sun; Xiaofeng Huang
Journal:  Tumour Biol       Date:  2016-09-21

3.  The effect of inhibiting exosomes derived from adipose-derived stem cells via the TGF-β1/Smad pathway on the fibrosis of keloid fibroblasts.

Authors:  Zhi-Yuan Wu; Hui-Jun Zhang; Zhi-Hong Zhou; Zhan-Peng Li; Si-Mu Liao; Ze-Yong Wu; Hai-Hua Huang; Yu-Cang Shi
Journal:  Gland Surg       Date:  2021-03

Review 4.  Human hypertrophic and keloid scar models: principles, limitations and future challenges from a tissue engineering perspective.

Authors:  Lenie J van den Broek; Grace C Limandjaja; Frank B Niessen; Susan Gibbs
Journal:  Exp Dermatol       Date:  2014-06       Impact factor: 3.960

Review 5.  New approach to the understanding of keloid: psychoneuroimmune-endocrine aspects.

Authors:  Bernardo Hochman; Felipe Contoli Isoldi; Fabianne Furtado; Lydia Masako Ferreira
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-02-10

6.  TGF-β1 Induces Polypyrimidine Tract-Binding Protein to Alter Fibroblasts Proliferation and Fibronectin Deposition in Keloid.

Authors:  Hu Jiao; Ping Dong; Li Yan; Zhigang Yang; Xiaoyan Lv; Qiuchen Li; Xianlei Zong; Jincai Fan; Xin Fu; Xia Liu; Ran Xiao
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

7.  High-Mobility Group Box 1 Mediates Fibroblast Activity via RAGE-MAPK and NF-κB Signaling in Keloid Scar Formation.

Authors:  Jihee Kim; Jong-Chul Park; Mi Hee Lee; Chae Eun Yang; Ju Hee Lee; Won Jai Lee
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

8.  Site-specific gene expression profiling as a novel strategy for unravelling keloid disease pathobiology.

Authors:  N Jumper; T Hodgkinson; R Paus; A Bayat
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

9.  Hypoxia-Induced Epithelial-To-Mesenchymal Transition Mediates Fibroblast Abnormalities via ERK Activation in Cutaneous Wound Healing.

Authors:  Jihee Kim; Bomi Kim; Soo Min Kim; Chae Eun Yang; Seung Yong Song; Won Jai Lee; Ju Hee Lee
Journal:  Int J Mol Sci       Date:  2019-05-24       Impact factor: 5.923

Review 10.  Basics of Radiation Biology When Treating Hyperproliferative Benign Diseases.

Authors:  Franz Rödel; Claudia Fournier; Julia Wiedemann; Felicitas Merz; Udo S Gaipl; Benjamin Frey; Ludwig Keilholz; M Heinrich Seegenschmiedt; Claus Rödel; Stephanie Hehlgans
Journal:  Front Immunol       Date:  2017-05-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.